Literature DB >> 12121964

Topoisomerase mutations associated with in vitro selection of resistance to moxifloxacin in Streptococcus pneumoniae.

Serge Houssaye1, Laurent Gutmann, Emmanuelle Varon.   

Abstract

We analyzed the frequencies of selection, the order of acquisition, and the mutations selected on moxifloxacin in two wild-type pneumococcal strains, R6 and 5714. The first selection step showed either a single GyrA mutation or no mutation in any of the quinolone resistance-determining regions. Second-step mutants selected had either a second mutation in ParC or in ParE. Moxifloxacin could belong to these fluoroquinolones, which preferentially target GyrA though probably acting equally through both gyrase and topoisomerase IV.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12121964      PMCID: PMC127326          DOI: 10.1128/AAC.46.8.2712-2715.2002

Source DB:  PubMed          Journal:  Antimicrob Agents Chemother        ISSN: 0066-4804            Impact factor:   5.191


  24 in total

1.  Prevalence of gyrA, gyrB, parC, and parE mutations in clinical isolates of Streptococcus pneumoniae with decreased susceptibilities to different fluoroquinolones and originating from Worldwide Surveillance Studies during the 1997-1998 respiratory season.

Authors:  M E Jones; D F Sahm; N Martin; S Scheuring; P Heisig; C Thornsberry; K Köhrer; F J Schmitz
Journal:  Antimicrob Agents Chemother       Date:  2000-02       Impact factor: 5.191

2.  Benchmarking the in vitro activity of moxifloxacin against recent isolates of Streptococcus pneumoniae, Moraxella catarrhalis, and Haemophilus influenzae. A European multi-centre study.

Authors:  M E Jones; A M Staples; I Critchley; C Thornsberry; P Heinze; H D Engler; D F Sahm
Journal:  Diagn Microbiol Infect Dis       Date:  2000-07       Impact factor: 2.803

3.  Comparative susceptibility to penicillin and quinolones of 1385 Streptococcus pneumoniae isolates. Austrian Bacterial Surveillance Network.

Authors:  A Buxbaum; U Straschil; C Moser; W Graninger; A Georgopoulos
Journal:  J Antimicrob Chemother       Date:  1999-05       Impact factor: 5.790

4.  Contribution of topoisomerase IV and DNA gyrase mutations in Streptococcus pneumoniae to resistance to novel fluoroquinolones.

Authors:  E Pestova; R Beyer; N P Cianciotto; G A Noskin; L R Peterson
Journal:  Antimicrob Agents Chemother       Date:  1999-08       Impact factor: 5.191

5.  Intracellular targets of moxifloxacin: a comparison with other fluoroquinolones.

Authors:  E Pestova; J J Millichap; G A Noskin; L R Peterson
Journal:  J Antimicrob Chemother       Date:  2000-05       Impact factor: 5.790

6.  Activities of clinafloxacin, gatifloxacin, gemifloxacin, and trovafloxacin against recent clinical isolates of levofloxacin-resistant Streptococcus pneumoniae.

Authors:  J H Jorgensen; L M Weigel; J M Swenson; C G Whitney; M J Ferraro; F C Tenover
Journal:  Antimicrob Agents Chemother       Date:  2000-11       Impact factor: 5.191

7.  Potent antipneumococcal activity of gemifloxacin is associated with dual targeting of gyrase and topoisomerase IV, an in vivo target preference for gyrase, and enhanced stabilization of cleavable complexes in vitro.

Authors:  V J Heaton; J E Ambler; L M Fisher
Journal:  Antimicrob Agents Chemother       Date:  2000-11       Impact factor: 5.191

8.  Fluoroquinolone resistance in clinical isolates of Streptococcus pneumoniae: contributions of type II topoisomerase mutations and efflux to levels of resistance.

Authors:  D J Bast; D E Low; C L Duncan; L Kilburn; L A Mandell; R J Davidson; J C de Azavedo
Journal:  Antimicrob Agents Chemother       Date:  2000-11       Impact factor: 5.191

9.  ParC and GyrA may be interchangeable initial targets of some fluoroquinolones in Streptococcus pneumoniae.

Authors:  E Varon; C Janoir; M D Kitzis; L Gutmann
Journal:  Antimicrob Agents Chemother       Date:  1999-02       Impact factor: 5.191

10.  Activities of newer fluoroquinolones against Streptococcus pneumoniae clinical isolates including those with mutations in the gyrA, parC, and parE loci.

Authors:  J H Jorgensen; L M Weigel; M J Ferraro; J M Swenson; F C Tenover
Journal:  Antimicrob Agents Chemother       Date:  1999-02       Impact factor: 5.191

View more
  17 in total

1.  Nonmolecular test for detection of low-level resistance to fluoroquinolones in Streptococcus pneumoniae.

Authors:  Emmanuelle Varon; Serge Houssaye; Sophie Grondin; Laurent Gutmann
Journal:  Antimicrob Agents Chemother       Date:  2006-02       Impact factor: 5.191

2.  Fluoroquinolone-resistant pneumococci: dynamics of serotypes and clones in Spain in 2012 compared with those from 2002 and 2006.

Authors:  Arnau Domenech; Jose M Tirado-Vélez; Asunción Fenoll; Carmen Ardanuy; Jose Yuste; Josefina Liñares; Adela G de la Campa
Journal:  Antimicrob Agents Chemother       Date:  2014-02-10       Impact factor: 5.191

3.  Nonoptimal DNA topoisomerases allow maintenance of supercoiling levels and improve fitness of Streptococcus pneumoniae.

Authors:  Luz Balsalobre; María José Ferrándiz; Gabriela de Alba; Adela G de la Campa
Journal:  Antimicrob Agents Chemother       Date:  2010-12-20       Impact factor: 5.191

4.  Molecular evaluation of antibiotic susceptibility: Tropheryma whipplei paradigm.

Authors:  F Masselot; A Boulos; M Maurin; J M Rolain; D Raoult
Journal:  Antimicrob Agents Chemother       Date:  2003-05       Impact factor: 5.191

5.  Fitness of Streptococcus pneumoniae fluoroquinolone-resistant strains with topoisomerase IV recombinant genes.

Authors:  Luz Balsalobre; Adela G de la Campa
Journal:  Antimicrob Agents Chemother       Date:  2007-12-26       Impact factor: 5.191

Review 6.  Moxifloxacin: a review of its use in the management of bacterial infections.

Authors:  Gillian M Keating; Lesley J Scott
Journal:  Drugs       Date:  2004       Impact factor: 9.546

7.  Mutations in topoisomerase genes of fluoroquinolone-resistant salmonellae in Hong Kong.

Authors:  J M Ling; E W Chan; A W Lam; A F Cheng
Journal:  Antimicrob Agents Chemother       Date:  2003-11       Impact factor: 5.191

8.  In vitro activities of garenoxacin (BMS-284756) against Streptococcus pneumoniae, viridans group streptococci, and Enterococcus faecalis compared to those of six other quinolones.

Authors:  Patrick Grohs; Serge Houssaye; Agnès Aubert; Laurent Gutmann; Emmanuelle Varon
Journal:  Antimicrob Agents Chemother       Date:  2003-11       Impact factor: 5.191

9.  Fluoroquinolone-resistant group B streptococci in acute exacerbation of chronic bronchitis.

Authors:  Asmaa Tazi; Thomas Gueudet; Emanuelle Varon; Liliane Gilly; Patrick Trieu-Cuot; Claire Poyart
Journal:  Emerg Infect Dis       Date:  2008-02       Impact factor: 6.883

10.  Changes in fluoroquinolone-resistant Streptococcus pneumoniae after 7-valent conjugate vaccination, Spain.

Authors:  Adela G de la Campa; Carmen Ardanuy; Luz Balsalobre; Emilio Pérez-Trallero; Jose M Marimón; Asunción Fenoll; Josefina Liñares
Journal:  Emerg Infect Dis       Date:  2009-06       Impact factor: 6.883

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.